BioTelemetry (NASDAQ:BEAT) Rating Increased to Hold at BidaskClub

BidaskClub upgraded shares of BioTelemetry (NASDAQ:BEAT) from a sell rating to a hold rating in a research note published on Saturday morning, BidAskClub reports.

A number of other equities research analysts have also recently commented on BEAT. TheStreet cut shares of BioTelemetry from a b- rating to a c+ rating in a research report on Friday, August 16th. ValuEngine upgraded shares of BioTelemetry from a hold rating to a buy rating in a research report on Wednesday, October 2nd. Lake Street Capital reiterated a buy rating and issued a $80.00 target price (down from $90.00) on shares of BioTelemetry in a research report on Wednesday. Raymond James cut shares of BioTelemetry from an outperform rating to a market perform rating in a research report on Friday, August 2nd. Finally, Sidoti reduced their target price on shares of BioTelemetry from $95.00 to $87.00 and set a buy rating for the company in a research report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $71.83.

Shares of BEAT stock traded up $1.25 during trading hours on Friday, hitting $45.80. The company’s stock had a trading volume of 309,700 shares, compared to its average volume of 463,447. The company has a current ratio of 2.19, a quick ratio of 2.09 and a debt-to-equity ratio of 0.54. The company has a 50 day moving average of $40.53 and a 200 day moving average of $45.18. The stock has a market cap of $1.46 billion, a PE ratio of 23.61, a price-to-earnings-growth ratio of 2.18 and a beta of 1.31. BioTelemetry has a 12-month low of $37.07 and a 12-month high of $80.92.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.52 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.02. The business had revenue of $111.30 million during the quarter, compared to analysts’ expectations of $111.19 million. BioTelemetry had a net margin of 8.98% and a return on equity of 22.27%. The company’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.53 earnings per share. As a group, analysts anticipate that BioTelemetry will post 1.97 earnings per share for the current fiscal year.

In other news, SVP Peter Ferola sold 44,276 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $39.03, for a total value of $1,728,092.28. Following the completion of the sale, the senior vice president now directly owns 19,622 shares in the company, valued at $765,846.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.50% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in BEAT. Amundi Pioneer Asset Management Inc. grew its holdings in shares of BioTelemetry by 34.4% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 45,700 shares of the medical research company’s stock valued at $2,862,000 after purchasing an additional 11,700 shares during the period. Cortina Asset Management LLC grew its holdings in shares of BioTelemetry by 21.3% in the second quarter. Cortina Asset Management LLC now owns 143,816 shares of the medical research company’s stock valued at $6,925,000 after purchasing an additional 25,280 shares during the period. New England Research & Management Inc. purchased a new stake in shares of BioTelemetry in the second quarter valued at about $549,000. Scout Investments Inc. grew its holdings in shares of BioTelemetry by 65.1% in the second quarter. Scout Investments Inc. now owns 208,760 shares of the medical research company’s stock valued at $10,052,000 after purchasing an additional 82,281 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of BioTelemetry in the second quarter valued at about $307,000. 91.19% of the stock is owned by hedge funds and other institutional investors.

BioTelemetry Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Further Reading: What moving averages are used to define a golden cross?

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.